Should a fetal fibronectin (FFN) test be repeated if the initial result was positive over two weeks ago?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Repeating a fetal fibronectin (FFN) test after a positive result two weeks ago is generally not recommended. The clinical implications of a positive result have not been evaluated fully because no intervention has been shown to decrease the risk of preterm delivery, as stated by the American College of Obstetricians and Gynecologists in 2002 1. Once a positive FFN result has been obtained, subsequent testing within 2-3 weeks provides limited additional clinical value because the protein can remain detectable for several weeks after release.

The initial positive result already indicates an increased risk of preterm birth within the next 7-14 days. However, it's essential to note that many women with positive FFN results do not deliver preterm. Management should focus on clinical assessment, including:

  • Monitoring for symptoms of preterm labor
  • Cervical length measurement by ultrasound, which is a reliable and reproducible way to assess the length of the cervix, as shown in prospective trials 1
  • Potentially initiating interventions such as corticosteroids for fetal lung maturity if preterm birth appears imminent

The FFN test is most useful as a negative predictor - a negative result has a high chance of no delivery within the next week, allowing clinicians to avoid unnecessary interventions. If clinical concerns persist beyond 2-3 weeks after the initial positive test, a new clinical assessment should guide management rather than repeat FFN testing. This approach prioritizes the patient's morbidity, mortality, and quality of life by avoiding unnecessary tests and interventions.

From the Research

Repeating a Positive Fetal Fibronectin (FFN) Test

  • The decision to repeat an FFN test after a positive result over two weeks ago should be based on the clinical context and the patient's individual risk factors for preterm labor 2, 3, 4.
  • Studies have shown that a positive FFN test is associated with an increased risk of preterm birth, but the predictive value of the test decreases over time 4, 5.
  • The sensitivity and specificity of FFN testing for predicting preterm birth vary depending on the population being studied and the gestational age at testing 2, 3, 4.
  • In patients with a cervical cerclage, FFN testing has been shown to be a valid diagnostic tool for evaluating preterm labor, but the test's performance characteristics may be affected by the presence of a cerclage 2, 3, 4.

Factors to Consider When Deciding to Repeat an FFN Test

  • The patient's individual risk factors for preterm labor, such as a history of preterm birth or cervical insufficiency 6.
  • The gestational age at the time of the initial positive FFN test and the current gestational age 4, 5.
  • The results of other diagnostic tests, such as cervical length measurement, and the patient's clinical symptoms 5.
  • The potential benefits and risks of repeating the FFN test, including the possibility of false positive or false negative results 3, 4.

Clinical Guidelines and Recommendations

  • The American College of Obstetricians and Gynecologists and other professional organizations have published guidelines for the diagnosis and management of preterm labor, but these guidelines do not specifically address the issue of repeating an FFN test after a positive result 6.
  • Clinical judgment and individualized decision-making are essential when determining whether to repeat an FFN test in a patient with a history of a positive result 2, 3, 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Fetal fibronectin for evaluation of preterm labor in the setting of cervical cerclage.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2012

Research

Fetal fibronectin as a predictor of spontaneous preterm labour in asymptomatic women with a cervical cerclage.

BJOG : an international journal of obstetrics and gynaecology, 2009

Research

Fetal fibronectin, cervical length, and the risk of preterm birth in patients with an ultrasound or physical exam indicated cervical cerclage.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.